Nitazoxanide is under clinical development by Genfit and currently in Phase I for Acute On Chronic Liver Failure (ACLF). According to GlobalData, Phase I drugs for Acute On Chronic Liver Failure (ACLF) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nitazoxanide LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nitazoxanide overview

Nitazoxanide is under development for the treatment of acute on chronic liver failure (ACLF), cirrhosis and sepsis. The drug candidate acts by targeting stellate cells. It is administered through oral route. It is a repurposed drug. It was also under development for cirrhosis.

It was also under development for liver fibrosis in non-alcoholic steatohepatitis patients.

Genfit overview

Genfit is a late-stage biopharmaceutical company. It develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include VS-01-ACLF, nitazoxanide (NTZ), inhibitor SRT-015, CLM-022, VS-02-HE, GNS561, VS-01-HAC, TS-01 and NIS2+. Genfit’s products are used in various therapeutic areas including acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemias (OA). Its products also include diagnostic tools for non-alcoholic steatohepatitis (NASH) and ammonia. The company works in collaboration with Genoscience Pharma, Ipsen Pharma, Seal Rock Therapeutics, Celloram, Labcorp, and Terns Pharmaceuticals for research and development. Genfit is headquartered in Loos, Hauts-de-France, France.

For a complete picture of Nitazoxanide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.